1 Introduction to Research & Analysis Reports
1.1 Mumps Vaccine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Mumps Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Mumps Vaccine Overall Market Size
2.1 Global Mumps Vaccine Market Size: 2022 VS 2029
2.2 Global Mumps Vaccine Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Mumps Vaccine Sales: 2018-2029
3 Company Landscape
3.1 Top Mumps Vaccine Players in Global Market
3.2 Top Global Mumps Vaccine Companies Ranked by Revenue
3.3 Global Mumps Vaccine Revenue by Companies
3.4 Global Mumps Vaccine Sales by Companies
3.5 Global Mumps Vaccine Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Mumps Vaccine Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Mumps Vaccine Product Type
3.8 Tier 1, Tier 2 and Tier 3 Mumps Vaccine Players in Global Market
3.8.1 List of Global Tier 1 Mumps Vaccine Companies
3.8.2 List of Global Tier 2 and Tier 3 Mumps Vaccine Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Mumps Vaccine Market Size Markets, 2022 & 2029
4.1.2 Child
4.1.3 Adult
4.2 By Type – Global Mumps Vaccine Revenue & Forecasts
4.2.1 By Type – Global Mumps Vaccine Revenue, 2018-2023
4.2.2 By Type – Global Mumps Vaccine Revenue, 2024-2029
4.2.3 By Type – Global Mumps Vaccine Revenue Market Share, 2018-2029
4.3 By Type – Global Mumps Vaccine Sales & Forecasts
4.3.1 By Type – Global Mumps Vaccine Sales, 2018-2023
4.3.2 By Type – Global Mumps Vaccine Sales, 2024-2029
4.3.3 By Type – Global Mumps Vaccine Sales Market Share, 2018-2029
4.4 By Type – Global Mumps Vaccine Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Mumps Vaccine Market Size, 2022 & 2029
5.1.2 Hospitals Pharmacies
5.1.3 Retail Pharmacies
5.2 By Application – Global Mumps Vaccine Revenue & Forecasts
5.2.1 By Application – Global Mumps Vaccine Revenue, 2018-2023
5.2.2 By Application – Global Mumps Vaccine Revenue, 2024-2029
5.2.3 By Application – Global Mumps Vaccine Revenue Market Share, 2018-2029
5.3 By Application – Global Mumps Vaccine Sales & Forecasts
5.3.1 By Application – Global Mumps Vaccine Sales, 2018-2023
5.3.2 By Application – Global Mumps Vaccine Sales, 2024-2029
5.3.3 By Application – Global Mumps Vaccine Sales Market Share, 2018-2029
5.4 By Application – Global Mumps Vaccine Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Mumps Vaccine Market Size, 2022 & 2029
6.2 By Region – Global Mumps Vaccine Revenue & Forecasts
6.2.1 By Region – Global Mumps Vaccine Revenue, 2018-2023
6.2.2 By Region – Global Mumps Vaccine Revenue, 2024-2029
6.2.3 By Region – Global Mumps Vaccine Revenue Market Share, 2018-2029
6.3 By Region – Global Mumps Vaccine Sales & Forecasts
6.3.1 By Region – Global Mumps Vaccine Sales, 2018-2023
6.3.2 By Region – Global Mumps Vaccine Sales, 2024-2029
6.3.3 By Region – Global Mumps Vaccine Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Mumps Vaccine Revenue, 2018-2029
6.4.2 By Country – North America Mumps Vaccine Sales, 2018-2029
6.4.3 US Mumps Vaccine Market Size, 2018-2029
6.4.4 Canada Mumps Vaccine Market Size, 2018-2029
6.4.5 Mexico Mumps Vaccine Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Mumps Vaccine Revenue, 2018-2029
6.5.2 By Country – Europe Mumps Vaccine Sales, 2018-2029
6.5.3 Germany Mumps Vaccine Market Size, 2018-2029
6.5.4 France Mumps Vaccine Market Size, 2018-2029
6.5.5 U.K. Mumps Vaccine Market Size, 2018-2029
6.5.6 Italy Mumps Vaccine Market Size, 2018-2029
6.5.7 Russia Mumps Vaccine Market Size, 2018-2029
6.5.8 Nordic Countries Mumps Vaccine Market Size, 2018-2029
6.5.9 Benelux Mumps Vaccine Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Mumps Vaccine Revenue, 2018-2029
6.6.2 By Region – Asia Mumps Vaccine Sales, 2018-2029
6.6.3 China Mumps Vaccine Market Size, 2018-2029
6.6.4 Japan Mumps Vaccine Market Size, 2018-2029
6.6.5 South Korea Mumps Vaccine Market Size, 2018-2029
6.6.6 Southeast Asia Mumps Vaccine Market Size, 2018-2029
6.6.7 India Mumps Vaccine Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Mumps Vaccine Revenue, 2018-2029
6.7.2 By Country – South America Mumps Vaccine Sales, 2018-2029
6.7.3 Brazil Mumps Vaccine Market Size, 2018-2029
6.7.4 Argentina Mumps Vaccine Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Mumps Vaccine Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Mumps Vaccine Sales, 2018-2029
6.8.3 Turkey Mumps Vaccine Market Size, 2018-2029
6.8.4 Israel Mumps Vaccine Market Size, 2018-2029
6.8.5 Saudi Arabia Mumps Vaccine Market Size, 2018-2029
6.8.6 UAE Mumps Vaccine Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 MedImmune
7.1.1 MedImmune Company Summary
7.1.2 MedImmune Business Overview
7.1.3 MedImmune Mumps Vaccine Major Product Offerings
7.1.4 MedImmune Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.1.5 MedImmune Key News & Latest Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Company Summary
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Mumps Vaccine Major Product Offerings
7.2.4 Johnson & Johnson Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.2.5 Johnson & Johnson Key News & Latest Developments
7.3 Merck & Co., Inc.
7.3.1 Merck & Co., Inc. Company Summary
7.3.2 Merck & Co., Inc. Business Overview
7.3.3 Merck & Co., Inc. Mumps Vaccine Major Product Offerings
7.3.4 Merck & Co., Inc. Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.3.5 Merck & Co., Inc. Key News & Latest Developments
7.4 Sanofi
7.4.1 Sanofi Company Summary
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Mumps Vaccine Major Product Offerings
7.4.4 Sanofi Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.4.5 Sanofi Key News & Latest Developments
7.5 Serum Institute of India
7.5.1 Serum Institute of India Company Summary
7.5.2 Serum Institute of India Business Overview
7.5.3 Serum Institute of India Mumps Vaccine Major Product Offerings
7.5.4 Serum Institute of India Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.5.5 Serum Institute of India Key News & Latest Developments
7.6 Bavarian Nordic
7.6.1 Bavarian Nordic Company Summary
7.6.2 Bavarian Nordic Business Overview
7.6.3 Bavarian Nordic Mumps Vaccine Major Product Offerings
7.6.4 Bavarian Nordic Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.6.5 Bavarian Nordic Key News & Latest Developments
7.7 Astellas Pharma India
7.7.1 Astellas Pharma India Company Summary
7.7.2 Astellas Pharma India Business Overview
7.7.3 Astellas Pharma India Mumps Vaccine Major Product Offerings
7.7.4 Astellas Pharma India Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.7.5 Astellas Pharma India Key News & Latest Developments
7.8 CSL Limited
7.8.1 CSL Limited Company Summary
7.8.2 CSL Limited Business Overview
7.8.3 CSL Limited Mumps Vaccine Major Product Offerings
7.8.4 CSL Limited Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.8.5 CSL Limited Key News & Latest Developments
7.9 Emergent BioSolutions
7.9.1 Emergent BioSolutions Company Summary
7.9.2 Emergent BioSolutions Business Overview
7.9.3 Emergent BioSolutions Mumps Vaccine Major Product Offerings
7.9.4 Emergent BioSolutions Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.9.5 Emergent BioSolutions Key News & Latest Developments
7.10 GlaxoSmithKline
7.10.1 GlaxoSmithKline Company Summary
7.10.2 GlaxoSmithKline Business Overview
7.10.3 GlaxoSmithKline Mumps Vaccine Major Product Offerings
7.10.4 GlaxoSmithKline Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.10.5 GlaxoSmithKline Key News & Latest Developments
7.11 Panacea Biotec, Ltd.
7.11.1 Panacea Biotec, Ltd. Company Summary
7.11.2 Panacea Biotec, Ltd. Mumps Vaccine Business Overview
7.11.3 Panacea Biotec, Ltd. Mumps Vaccine Major Product Offerings
7.11.4 Panacea Biotec, Ltd. Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.11.5 Panacea Biotec, Ltd. Key News & Latest Developments
7.12 Biological E Limited
7.12.1 Biological E Limited Company Summary
7.12.2 Biological E Limited Mumps Vaccine Business Overview
7.12.3 Biological E Limited Mumps Vaccine Major Product Offerings
7.12.4 Biological E Limited Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.12.5 Biological E Limited Key News & Latest Developments
7.13 Bharat Biotech Ltd.
7.13.1 Bharat Biotech Ltd. Company Summary
7.13.2 Bharat Biotech Ltd. Mumps Vaccine Business Overview
7.13.3 Bharat Biotech Ltd. Mumps Vaccine Major Product Offerings
7.13.4 Bharat Biotech Ltd. Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.13.5 Bharat Biotech Ltd. Key News & Latest Developments
7.14 Novavax, Inc.
7.14.1 Novavax, Inc. Company Summary
7.14.2 Novavax, Inc. Business Overview
7.14.3 Novavax, Inc. Mumps Vaccine Major Product Offerings
7.14.4 Novavax, Inc. Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.14.5 Novavax, Inc. Key News & Latest Developments
7.15 Novartis
7.15.1 Novartis Company Summary
7.15.2 Novartis Business Overview
7.15.3 Novartis Mumps Vaccine Major Product Offerings
7.15.4 Novartis Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.15.5 Novartis Key News & Latest Developments
7.16 Sinovac Biotech, Ltd.
7.16.1 Sinovac Biotech, Ltd. Company Summary
7.16.2 Sinovac Biotech, Ltd. Business Overview
7.16.3 Sinovac Biotech, Ltd. Mumps Vaccine Major Product Offerings
7.16.4 Sinovac Biotech, Ltd. Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.16.5 Sinovac Biotech, Ltd. Key News & Latest Developments
7.17 Incepta Vaccine Limited
7.17.1 Incepta Vaccine Limited Company Summary
7.17.2 Incepta Vaccine Limited Business Overview
7.17.3 Incepta Vaccine Limited Mumps Vaccine Major Product Offerings
7.17.4 Incepta Vaccine Limited Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.17.5 Incepta Vaccine Limited Key News & Latest Developments
7.18 Valneva SE
7.18.1 Valneva SE Company Summary
7.18.2 Valneva SE Business Overview
7.18.3 Valneva SE Mumps Vaccine Major Product Offerings
7.18.4 Valneva SE Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.18.5 Valneva SE Key News & Latest Developments
7.19 VBI Vaccines
7.19.1 VBI Vaccines Company Summary
7.19.2 VBI Vaccines Business Overview
7.19.3 VBI Vaccines Mumps Vaccine Major Product Offerings
7.19.4 VBI Vaccines Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.19.5 VBI Vaccines Key News & Latest Developments
7.20 PT Bio Farma
7.20.1 PT Bio Farma Company Summary
7.20.2 PT Bio Farma Business Overview
7.20.3 PT Bio Farma Mumps Vaccine Major Product Offerings
7.20.4 PT Bio Farma Mumps Vaccine Sales and Revenue in Global (2018-2023)
7.20.5 PT Bio Farma Key News & Latest Developments
8 Global Mumps Vaccine Production Capacity, Analysis
8.1 Global Mumps Vaccine Production Capacity, 2018-2029
8.2 Mumps Vaccine Production Capacity of Key Manufacturers in Global Market
8.3 Global Mumps Vaccine Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Mumps Vaccine Supply Chain Analysis
10.1 Mumps Vaccine Industry Value Chain
10.2 Mumps Vaccine Upstream Market
10.3 Mumps Vaccine Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Mumps Vaccine Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
※参考情報 おたふく風邪ワクチンは、流行性耳下腺炎を引き起こすおたふく風邪ウイルスに対する免疫を生成するために用いられるワクチンです。流行性耳下腺炎は、主におたふく風邪ウイルスによって引き起こされる感染症であり、特に子供に多く見られますが、大人にも感染することがあります。このウイルスは、特に耳下腺が腫れることが特徴で、発熱や頭痛、筋肉痛も伴うことがあります。 おたふく風邪ワクチンは、ウイルスに対する免疫応答を促進するために使用され、主に小児の予防接種プログラムに組み込まれています。ウイルスが体内に侵入した際、免疫系は抗体を生成し、将来的にウイルスに再感染しないようにするのです。このワクチンは、ウイルスの生ワクチンまたは不活化ワクチンのどちらかの形でいますが、現在は生ワクチンが主流です。 特徴としては、接種後数週間から数ヶ月で免疫が形成されるため、長期間にわたる感染予防が期待できる点が挙げられます。生ワクチンの場合、ウイルスが弱毒化されているため、症状が軽くなることが多く、接種者の健康状態にあまり影響を与えません。また、ワクチン接種は乳幼児期から始められるため、早期に免疫を獲得することができます。 おたふく風邪ワクチンの種類には、単独ワクチンと三種混合ワクチン(MMR)があります。三種混合ワクチンは、おたふく風邪の他に、麻疹(はしか)と風疹に対する免疫を同時に提供するため、効率的です。これは、乳幼児期における接種スケジュールの一環として多くの国で推奨されており、複数の感染症から子供を守るための有効な手段となっています。 おたふく風邪ワクチンの用途は多岐にわたります。まず、流行性耳下腺炎の予防が最も基本的な目的です。また、発症を防ぐことに加え、感染の拡大を抑制する役割も果たします。特に集団生活をする機会の多い子供たちにとっては、ワクチン接種によって集団免疫が形成され、ひとりひとりを守ることに繋がります。さらに、成人においても場合によっては重篤な合併症を引き起こす可能性があるため、成人の接種も重要です。 関連技術としては、ワクチン生成における細胞培養技術や遺伝子工学技術が挙げられます。生ワクチンは通常、弱毒化ウイルスを使用しますが、これは特定の細胞培養技術によって作り出されます。遺伝子工学の進展により、ワクチンの効果を向上させたり、安全性を向上させるための新たな技術が開発されつつあります。 実際の接種方法は、通常は皮下注射または筋肉内注射で行われます。接種後には一時的に軽い副反応、例えば発熱や発疹が見られることがありますが、重篤な副作用は極めて稀です。個人の健康状態やアレルギー歴に応じて、医師が判断し、接種を行います。 また、ワクチンに関する正しい情報提供も重要です。信頼性のある情報源からの知識をもって、ワクチン接種の重要性や感染症予防について理解を深めることは、社会全体の健康に寄与します。きちんとしたワクチン接種により、多くの感染症を防ぎ、結果として公衆衛生の向上に繋がります。 最後に、おたふく風邪ワクチンは世界中で広く使用されていますが、国や地域によって接種スケジュールや推奨事項が異なることもあります。各国の保健機関の指針に従った接種が求められるため、最新の情報を確認し、適切な対応をとることが重要です。ワクチンは、感染症予防のための強力なツールであり、地域社会全体を守るための重要な施策の一環であることを認識する必要があります。このように、おたふく風邪ワクチンは、個人の健康を守るだけでなく、集団の健康を維持するための重要な役割を果たしています。 |